The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback